Melatonin: a promising therapy to combat type 2 airway inflammation via MT1-Sirt1 pathway
Frontiers in Pharmacology · 17.04.2026 · 17
DOI: 10.3389/fphar.2026.1805178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.04.2026. Verfasst von Zhe Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Physical Examination Center, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Provincial Key Laboratory for Interventional Medical Devices.
Abstract (Originalsprache)
Backgrounds Type 2 asthma is characterized by airway inflammation, mucus hypersecretion, and remodeling, and circadian rhythm dysregulation is implicated in its pathogenesis. Melatonin, a key circadian hormone, modulates inflammatory signaling, but its role in type 2 airway inflammation remains unclear. This study investigated whether melatonin alleviates airway inflammation and epithelial-mesenchymal transition (EMT) through the melatonin receptor 1 (MT1)-Sirtuin 1 (Sirt1) signaling pathway and circadian clock regulation.
Methods
An ovalbumin (OVA)-induced mouse model of type 2 airway inflammation and cultured airway epithelial cells were used. Lung structural remodeling and mucus production were evaluated using hematoxylin and eosin, Masson’s trichrome, and periodic acid–Schiff staining. Airway inflammation was assessed by differential inflammatory cell counts in bronchoalveolar lavage fluid. The mRNA and protein expression of circadian clock genes (CRY1 and PER1) and key components of the MT1–Sirt1 pathway were assessed by quantitative real-time PCR, Western blotting, and immunohistochemistry. EMT-related markers were further examined to explore downstream mechanisms.
Results
Melatonin treatment activated MT1-Sirt1 signaling and reduced the expression of circadian clock genes CRY1 and PER1. These effects were accompanied by decreased airway inflammation, reduced mucus production, and attenuation of epithelial-mesenchymal transition (EMT) in airway epithelial cells, all of which reached statistical significance.
Conclusion
Our findings identify a novel MT1–Sirt1–circadian gene regulatory axis through which melatonin mitigates type 2 airway inflammation and airway remodeling. These results highlight the therapeutic potential of melatonin for type 2 asthma. Limitations include the use of a single animal model and analysis at a single time point.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Physical Examination Center, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
- Department of Respiratory Medicine, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
- Department of Respiration Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Förderung
- Jiangsu Provincial Key Laboratory for Interventional Medical Devices
Zitieren
APA
Zhang, Z., Jiang, J., Chen, G., Zhang, X., Wang, J., & Wang, B. (2026). Melatonin: a promising therapy to combat type 2 airway inflammation via MT1-Sirt1 pathway. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1805178
Vancouver
Zhang Z, Jiang J, Chen G, Zhang X, Wang J, Wang B. Melatonin: a promising therapy to combat type 2 airway inflammation via MT1-Sirt1 pathway. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1805178
BibTeX
@article{Zhang2026,
author = {Zhang, Zhe and Jiang, Jie and Chen, Guilian and Zhang, Xiuqin and Wang, Jipeng and Wang, Baolan},
title = {Melatonin: a promising therapy to combat type 2 airway inflammation via MT1-Sirt1 pathway},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1805178}
}
EUVIMED